The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors.
 
Xiangdong Cheng
No Relationships to Disclose
 
Zhengbo Song
No Relationships to Disclose
 
Jian Zhang
No Relationships to Disclose
 
Jianan Jin
No Relationships to Disclose
 
Shuiping Gao
No Relationships to Disclose
 
Rujiao Liu
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Yan Zhang
No Relationships to Disclose
 
Shegan Gao
No Relationships to Disclose
 
Ruinuo Jia
No Relationships to Disclose
 
Deqiang Jing
Employment - ImmuneOnco Biopharmaceuticals
 
Yu Xu
Employment - ImmuneOnco Biopharmaceuticals
 
Lina Zheng
Employment - ImmuneOnco Biopharmaceuticals
 
Xiwen Zhao
Employment - ImmuneOnco Biopharmaceuticals
 
Wei Li
Employment - ImmuneOnco Biopharmaceuticals
 
Qiying Lu
Employment - ImmuneOnco Biopharmaceuticals
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals
 
Wenzhi Tian
Employment - ImmuneOnco Biopharmaceuticals
Leadership - ImmuneOnco Biopharmaceuticals
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals
 
Xichun Hu
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Hengrui Pharmaceutical; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca